English

• 

• 1. [1] (a) E. de Clercq, P. Herdewijn, Strategies in the design of antiviral drugs, Nat. Rev. Drug Discov. 1 (2002) 13-25; (b) E. de Clercq, Molecular targets for antiviral agents, J. Pharmacol. Exp. Ther. 297 (2001) 1-10.[1] (a) E. de Clercq, P. Herdewijn, Strategies in the design of antiviral drugs, Nat. Rev. Drug Discov. 1 (2002) 13-25; (b) E. de Clercq, Molecular targets for antiviral agents, J. Pharmacol. Exp. Ther. 297 (2001) 1-10.

  2. [2] B.Öberg, Rational design of polymerase inhibitors as antiviral drugs, Antivir. Res. 71 (2006) 90-95.[2] B.Öberg, Rational design of polymerase inhibitors as antiviral drugs, Antivir. Res. 71 (2006) 90-95.

  3. [3] (a) E. de Clercq, J. Neyts, Antiviral agents acting as DNA or RNA chain terminators, Handb. Exp. Pharmacol. 189 (2009) 53-84; (b) X.J. Liu, W. Xie, R.H. Huang, Structure-based design, synthesis, and in vitro assay of novel nucleoside analog inhibitors against HIV-1 reverse transcriptase, Bioorg. Med. Chem. Lett. 15 (2005) 3775-3777.[3] (a) E. de Clercq, J. Neyts, Antiviral agents acting as DNA or RNA chain terminators, Handb. Exp. Pharmacol. 189 (2009) 53-84; (b) X.J. Liu, W. Xie, R.H. Huang, Structure-based design, synthesis, and in vitro assay of novel nucleoside analog inhibitors against HIV-1 reverse transcriptase, Bioorg. Med. Chem. Lett. 15 (2005) 3775-3777.

  4. [4] (a) Q. Ma, I.C. Bathurst, P.J. Barr, G.L. Kenyon, New thymidine triphosphate analogue inhibitors of human immunodeficiency virus-1 reverse transcriptase, J. Med. Chem. 35 (1992) 1938-1941; (b) A. Fatima, C. Christophe, G. Jacques, G. Roger, D. Daniele, The production and evaluation of antibodies for enzyme immunoassay of AZTTP, Nucleos. Nucleot. Nucl. 20 (2001) 243-250; (c) M.M. Mansuri, J.E. Starrett, I. Ghazzouli, et al., 1-(2,3-Dideoxy-b-D-glyceropent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent, J. Med. Chem. 32 (1989) 461-466.[4] (a) Q. Ma, I.C. Bathurst, P.J. Barr, G.L. Kenyon, New thymidine triphosphate analogue inhibitors of human immunodeficiency virus-1 reverse transcriptase, J. Med. Chem. 35 (1992) 1938-1941; (b) A. Fatima, C. Christophe, G. Jacques, G. Roger, D. Daniele, The production and evaluation of antibodies for enzyme immunoassay of AZTTP, Nucleos. Nucleot. Nucl. 20 (2001) 243-250; (c) M.M. Mansuri, J.E. Starrett, I. Ghazzouli, et al., 1-(2,3-Dideoxy-b-D-glyceropent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent, J. Med. Chem. 32 (1989) 461-466.

  5. [5] J. Ludwig, F. Eckstein, Rapid and efficient synthesis of nucleoside 5'-O-(1-thiotriphosphates), 5'-triphosphates, and 2',3'-cyclophosphorothioates using 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one, J. Org. Chem. 54 (1989) 631-635.[5] J. Ludwig, F. Eckstein, Rapid and efficient synthesis of nucleoside 5'-O-(1-thiotriphosphates), 5'-triphosphates, and 2',3'-cyclophosphorothioates using 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one, J. Org. Chem. 54 (1989) 631-635.

  6. [6] M. Mauro, C. Anna, F. Alessandra, et al., Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection, Proc. Natl. Acad. Sci. USA 93 (1996) 4403-4408.[6] M. Mauro, C. Anna, F. Alessandra, et al., Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection, Proc. Natl. Acad. Sci. USA 93 (1996) 4403-4408.

  7. [7] L. Rossi, S. Serafini, P. Franchetti, et al., Targeting nucleotide dimers containing antiviral nucleosides, Curr. Med. Chem. Anti-Infect. Agents 4 (2005) 37-54.[7] L. Rossi, S. Serafini, P. Franchetti, et al., Targeting nucleotide dimers containing antiviral nucleosides, Curr. Med. Chem. Anti-Infect. Agents 4 (2005) 37-54.

  8. [8] S.Q. Yang, C. Pannecouque, P. Herdewijn, Synthesis and in vitro enzymatic and antiviral evaluation of d4T polyphosphate derivatives as chain terminators, Chem. Biodiv. 9 (2012) 2186-2194.[8] S.Q. Yang, C. Pannecouque, P. Herdewijn, Synthesis and in vitro enzymatic and antiviral evaluation of d4T polyphosphate derivatives as chain terminators, Chem. Biodiv. 9 (2012) 2186-2194.

  9. [9] Y. Ahmadibeni, K. Parang, Selective diphosphorylation dithiodiphosphorylation triphosphorylation and trithiotriphosphorylation of unprotected carbohydrates and nuclesides, Org. Lett. 7 (2005) 5589-5592.[9] Y. Ahmadibeni, K. Parang, Selective diphosphorylation dithiodiphosphorylation triphosphorylation and trithiotriphosphorylation of unprotected carbohydrates and nuclesides, Org. Lett. 7 (2005) 5589-5592.

  10. [10] I. Lindh, J. Stawinski, A general method for the synthesis of glycerophospholipids and their analogs via H-phosphonate intermediates, J. Org. Chem. 54 (1989) 1338-1342.[10] I. Lindh, J. Stawinski, A general method for the synthesis of glycerophospholipids and their analogs via H-phosphonate intermediates, J. Org. Chem. 54 (1989) 1338-1342.

  11. [11] Q. Sun, S. Liu, J. Sun, et al., One-pot synthesis of symmetrical P¹,P²-dinucleoside-50-diphosphates from nucleoside-5'-H-phosphonates: mechanistic insights into reaction path, Tetrahedron Lett. 54 (2013) 3842-3845.[11] Q. Sun, S. Liu, J. Sun, et al., One-pot synthesis of symmetrical P¹,P²-dinucleoside-50-diphosphates from nucleoside-5'-H-phosphonates: mechanistic insights into reaction path, Tetrahedron Lett. 54 (2013) 3842-3845.

  12. [12] Q. Sun, J.P. Edathil, R. Wu, et al., One-pot synthesis of nucleoside 5'-triphosphates from nucleoside 50-H-phosphonates, Org. Lett. 10 (2008) 1703-1706.[12] Q. Sun, J.P. Edathil, R. Wu, et al., One-pot synthesis of nucleoside 5'-triphosphates from nucleoside 50-H-phosphonates, Org. Lett. 10 (2008) 1703-1706.

  13. [13] R. Wu, E.D. Smidansky, H.S. Oh, et al., Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses, J. Med. Chem. 53 (2010) 7958-7966.[13] R. Wu, E.D. Smidansky, H.S. Oh, et al., Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses, J. Med. Chem. 53 (2010) 7958-7966.

  14. [14] (a) D.G. Knorre, A.V. Lebedev, A.S. Levina, A.I. Rezvukhin, V.F. Zarytova, Active monomeric nucleotide intermediate in the oligonucleotide synthesis, Tetrahedron 30 (1974) 3073-3079; (b) M. Sekine, M. Ushioda, T. Wada, K. Seio, Synthesis of TMG-capped RNA-DNA chimeric oligonucleotides, Tetrahedron Lett. 44 (2003) 1703-1707.[14] (a) D.G. Knorre, A.V. Lebedev, A.S. Levina, A.I. Rezvukhin, V.F. Zarytova, Active monomeric nucleotide intermediate in the oligonucleotide synthesis, Tetrahedron 30 (1974) 3073-3079; (b) M. Sekine, M. Ushioda, T. Wada, K. Seio, Synthesis of TMG-capped RNA-DNA chimeric oligonucleotides, Tetrahedron Lett. 44 (2003) 1703-1707.

  15. [15] Q. Sun, S. Gong, J. Sun, et al., A P(V)-N activation strategy for synthesis of nucleoside polyphosphates, J. Org. Chem. 78 (2013) 8417-8426.[15] Q. Sun, S. Gong, J. Sun, et al., A P(V)-N activation strategy for synthesis of nucleoside polyphosphates, J. Org. Chem. 78 (2013) 8417-8426.

•